| Patient | Abraham Lincoln |
|---|---|
| Date of birth | 1994-02-12 |
| Identifiers | MRN HR-NI001-SYN; SSN (made up) 000-01-6683 |
| Document date | 2026-08-11 |
| Author | Elena Marquez, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week depression treatment follow-up. [S]
Mr. Lincoln returns six weeks after starting sertraline 50 mg daily for a moderate depressive episode. His mood is brighter on most days, and he is enjoying his work again. He is back at court on his usual schedule and writes letters to friends two or three times a week. He falls asleep within half an hour and wakes once a night, compared with the broken sleep he described at intake, and his concentration on long briefs is better. Mild nausea in the first two weeks settled by the third week. He has had no headache, diarrhea, restlessness, or sexual side effects. He misses about one dose every two weeks. He has had no suicidal thoughts since the intake visit and still carries his safety plan. He drinks no alcohol. He saw Dr. Natarajan of psychiatry this morning. [S]
| Element | Detail |
|---|---|
| Interval change | Mood brighter on most days; back to court work and letters to friends |
| Sleep | Asleep within half an hour; wakes once a night |
| Medication tolerance | Nausea resolved by week three; no other adverse effects |
| Adherence | Misses about one dose every two weeks |
| Safety | No suicidal thoughts since intake; safety plan carried |
| PHQ-9 | 9, down from 14 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no weight change of note |
| Gastrointestinal | Negative | Early nausea resolved; no diarrhea, heartburn, or bleeding |
| Genitourinary | Negative | No sexual side effects |
| Neurological | Negative | No headache, tremor, or restlessness |
| Psychiatric | Positive | Low mood easing but not gone; sleep and concentration better; no suicidal thoughts, elevated mood, or racing thoughts |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-11 | Body height | 193 | cm | S |
| 2026-08-11 | Body weight | 82.4 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 70 | /min | S |
| 2026-08-11 | Respiratory rate | 14 | /min | S |
| 2026-08-11 | Body temperature | 36.8 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S |
Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tall, neatly dressed, comfortable, and engaged |
| Mental status | Alert and oriented; mood "better, not yet myself"; affect mildly constricted but brighter and reactive, with humor; thought process linear; no suicidal ideation or psychotic features; insight and judgment good |
| Neurological | No tremor; gait normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Major depressive disorder, single episode, moderate; synthetic modern diagnosis linked to documented low mood and its retrospective interpretation | active | provisional | F32.1 | S — Synthetic active diagnosis for the teaching episode; the historical depression label remains R. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 9, down from 14 at intake (36 percent): partial response, not yet the 50 percent reduction that defines response |
| Survey | PHQ-9 at four weeks | At least monthly during acute treatment | Deferred | Not done: the care plan set the first review at six weeks, so no score was taken at four weeks, a deviation from the protocol. No harm resulted: today's score has fallen 5 points and he has no suicidal thoughts. Corrective action: a nurse telephone PHQ-9 in about four weeks, so the seven weeks to the twelve-week review are not left unmeasured |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the intake visit; PHQ-9 item 9 scored 0. Protective factors unchanged. Collaborative safety plan reviewed with him: he carries his copy and has 988 and the clinic number saved |
| Medication safety | Sertraline tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Deferred | Not done: no contact was scheduled between the intake visit and today, a deviation from the protocol, which also calls for closer contact in the first weeks of an antidepressant. No harm resulted judging by today's review: the mild nausea settled by the third week, and he has had no restlessness, agitation, or suicidal thoughts. Corrective action: a nurse telephone check one to two weeks after any future start or dose change is now in his plan |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | Misses about one dose every two weeks; nausea resolved; no headache, diarrhea, tremor, restlessness, sexual side effects, bruising, or bleeding |
| Survey | Mood Disorder Questionnaire (bipolar screen) | Once at the initial depression workup | Deferred | Not given at intake, a deviation from the protocol. Dr. Natarajan's interview today found no past periods of elevated or irritable mood, reduced need for sleep, or racing thoughts, so bipolar disorder is not suspected, and no harm resulted: he has had no activation on sertraline. The questionnaire will be used if hypomanic features appear |
| Examination | Weight, BMI, and blood pressure | Baseline metabolic review, then with each tolerability check | Completed today | Weight 82.4 kg, up 0.4 kg since intake; BMI 22.1; blood pressure 116/72 mmHg |
| Examination | Mental status examination | Every visit | Completed today | Brighter, reactive affect; linear thinking; no suicidal ideation or psychotic features |
| Laboratory | Drug levels and metabolic laboratory monitoring | Lithium, valproate, carbamazepine, or second-generation antipsychotic therapy | Not indicated | Sertraline monotherapy needs no routine laboratory monitoring |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Every 6 months on antipsychotic therapy | Not indicated | No antipsychotic medicine |
| Referral | Psychiatry consultation | At diagnosis, as the care plan specifies | Completed today | Seen by Dr. Natarajan this morning. She agrees with the diagnosis and with sertraline monotherapy, found no bipolar or psychotic features, and judged acute suicide risk low |
| Self-management | Behavioral activation: two valued activities each week | Every visit | Completed today | Court work and letters to friends resumed; goal met |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse telephone check with a PHQ-9 in about four weeks. Twelve-week depression review in seven weeks. Call the clinic or 988 at any time if his mood worsens or suicidal thoughts appear. Next scheduled visit 2026-09-30: twelve-week depression care-plan review. [S]